Results for "antiviral"
ViiV Healthcare announces phase III study meets primary endpoint, demonstrating the ability to control HIV-1 with a 2-drug regimen of dolutegravir plus lamivudine in virally suppressed patients switching from a TAF-containing, 3-drug regimen
First published: 10 July 2019
Week 48 results from the TANGO study will be presented this month at 10th International AIDS Society Conference on HIV Science (IAS 2019).
ViiV Healthcare announces positive Week 48 results in first study to evaluate treatment switch from TAF-containing regimen with three or more drugs to 2-drug regimen of dolutegravir/lamivudine for HIV-1 infection
First published: 24 July 2019
Data from the TANGO study presented at the 10th International AIDS Society Conference on HIV Science (IAS 2019) demonstrate non-inferior efficacy of Dovato▼ (dolutegravir/lamivudine) in virally sup...
ViiV Healthcare Announces CHMP positive opinion to lower the age and weight limit for Tivicay® (dolutegravir) in children and adolescents living with HIV in Europe
First published: 16 December 2016
The CHMP has adopted a positive opinion to reduce the weight and age limit for the treatment of HIV with Tivicay.
ViiV Healthcare receives EU marketing authorisation for Triumeq® (dolutegravir/abacavir/lamivudine), a new once-daily single-pill regimen for the treatment of HIV
First published: 03 September 2014
ViiV Healthcare announced today that the European Commission (EC) has granted marketing authorisation for Triumeq® (dolutegravir 50mg / abacavir 600mg / lamivudine 300mg) tablets for the treatment ...
ViiV Healthcare presents data from Phase III study of dolutegravir vs raltegravir in treatment-experienced adults with HIV-1
First published: 06 March 2013
ViiV Healthcare presents 24-week interim results from Phase III SAILING study at the 20th Conference on Retroviruses and Opportunistic Infections (CROI)
Shionogi-ViiV Healthcare announces completion of initial clinical registration package for dolutegravir in HIV
First published: 04 October 2012
Shionogi-ViiV Healthcare LLC today announced that the phase III data required for initial regulatory filings of the investigational integrase inhibitor dolutegravir in adults infected with HIV are ...
GSK and Enigma Diagnostics announce commercial partnership to develop point-of-care influenza diagnostics
First published: 20 July 2009
GlaxoSmithKline (GSK) and Enigma Diagnostics Limited today announced that they have signed worldwide agreements to develop and supply the first point-of-care diagnostic influenza tests to identify ...
GSK and Concert Pharmaceuticals form alliance to develop novel deuterium-modified drugs
First published: 01 June 2009
GlaxoSmithKline (NYSE: GSK) and Concert Pharmaceuticals announced today that they will collaborate to develop and commercialise deuterium-containing medicines. The deal includes three of Concert...
GlaxoSmithKline update: influenza A (H1N1)
First published: 30 April 2009
GlaxoSmithKline (GSK) is committed to supporting governments and health authorities around the world to respond to the emergence of the new influenza A (H1N1) strain.
Phase II study results showed comparable viral suppression rates at 96 weeks for a two-drug regimen of long-acting cabotegravir and rilpivirine and a three-drug regimen in patients with HIV
First published: 24 July 2017
LATTE-2 study results published in The Lancet and presented at International AIDS Society Meeting